Framework Personalizes Glioma Radiotherapy
In a Nature Communications publication, researchers introduce GliODIL, a computational framework that personalizes radiotherapy planning for glioma patients by integrating tumor growth models with MRI and PET imaging data. With contributions from the Menze Lab, GliODIL was validated on 152 glioblastoma patients, demonstrating improved predictions of recurrence locations compared to standard uniform-margin approaches. This framework achieved better tumor coverage while maintaining treatment volumes, showing potential to enhance treatment efficacy and minimize side effects. GliODIL exemplifies the power of combining biophysical modeling and patient data to advance precision radiotherapy in neuro-oncology.
Publication Link: https://doi.org/10.1038/s41467-025-60366-4
